BridgeBio Pharma Inc
$ 84.48
2.03%
07 Aug - close price
- Market Cap 16,546,359,000 USD
- Current Price $ 84.48
- High / Low $ 85.03 / 82.24
- Stock P/E N/A
- Book Value -11.64
- EPS -3.74
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -17.90 %
- 52 Week High 93.42
- 52 Week Low 46.28
About
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Analyst Target Price
$106.19
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-24 | 2025-10-29 | 2025-08-05 | 2025-04-29 | 2025-02-20 | 2024-11-12 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.84 | -0.9389 | -0.72 | -0.95 | -0.9888 | -1.3744 | -0.8596 | -1.01 | -0.12 | -0.96 | -1.08 | -0.96 |
| Estimated EPS | -0.62 | -0.716 | -0.78 | -0.6 | -0.89 | -1.09 | -0.98 | -0.94 | -0.54 | -0.91 | -0.89 | -0.87 |
| Surprise | -0.22 | -0.2229 | 0.06 | -0.35 | -0.0988 | -0.2844 | 0.1204 | -0.07 | 0.42 | -0.05 | -0.19 | -0.09 |
| Surprise Percentage | -35.4839% | -31.1313% | 7.6923% | -58.3333% | -11.1011% | -26.0917% | 12.2857% | -7.4468% | 77.7778% | -5.4945% | -21.3483% | -10.3448% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.64 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BBIO
2026-08-09 03:10:36
This article analyzes Bridgebio Pharma Inc. (BBIO) through quantitative research, highlighting a strong near-term sentiment with a long-term positive bias. It presents an exceptional risk-reward setup targeting a 13.9% gain, along with three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis also provides multi-timeframe signal insights, including support and resistance levels.
2026-08-07 23:41:37
BridgeBio Pharma, Inc. is projected to report a loss of 58 cents per share in its upcoming earnings. This information is provided as an earnings preview by Reuters, distributed through TradingView News. The article suggests that readers can access more details on TradingView.
2026-08-06 19:11:19
BridgeBio Pharma (BBIO) recently received FDA acceptance for its New Drug Application for encaleret, a potential first-in-class therapy for autosomal dominant hypocalcemia type 1, and filed two shelf registrations for US$2.21 billion in common stock. These developments could significantly alter BridgeBio's investment narrative by providing a new revenue stream and financial flexibility, potentially mitigating risks associated with high R&D spend and net losses. Despite the positive catalyst, investors should remain aware of ongoing high costs and the possibility of future equity raises.
2026-08-04 09:15:09
Piper Sandler has reiterated its Buy rating on BridgeBio Pharma (BBIO.US) and maintained a target price of $111. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
2026-08-04 05:14:04
BridgeBio Pharma (BBIO) stock has seen a significant 148% return over the last three years but appears to be priced at a premium, with a current Price/Sales (P/S) ratio of 27.0x, significantly higher than the biotech industry average. Despite FDA acceptance for its key drug candidate, encaleret, the valuation checks suggest the stock leans expensive. Investors are weighing whether the current price reflects too much optimism, given potential execution risks and the gap between its current P/S and a fair P/S of 21.6x.
2026-08-03 23:41:37
Maricel Apuli, CAO of BridgeBio Pharma (NASDAQ:BBIO), sold 2,000 shares for $160,120 under a pre-arranged trading plan, retaining 127,401 shares. The company's shares traded down 0.2% to $79.96, despite strong revenue growth of 66.8% year-over-year, as it missed EPS expectations. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $95.21.
